American Heart Association Praises Califf Nomination for FDA Commissioner

September 17, 2015 Categories: Advocacy News

Washington, D.C., Sept. 17, 2015 – American Heart Association CEO Nancy Brown issued the following comments today on the nomination of Robert M. Califf, M.D. as the next commissioner of the Food and Drug Administration (FDA): 

“The next FDA commissioner will need to be skilled in working with all stakeholders to protect and improve the health of all Americans. We believe Dr. Califf is the perfect person for this job. 

His distinguished career in medicine and clinical research makes him ideally suited to lead the FDA. As a cardiologist, his approach has been especially patient-centric. As a researcher, he has been an outstanding collaborator whose groundbreaking contributions to science have moved the field forward. Dr. Califf also brings significant leadership experience to this position, first as the founding director of the Duke Clinical Research Institute, and now in his current role as the Deputy Commissioner of Medical Products and Tobacco. 

As a member of the association, Dr. Califf has been strongly committed to the fight against heart disease and stroke. One of his notable accomplishments was to assist us with the design of a community program in the state of North Carolina, which helped residents maintain a healthy blood pressure through monitoring and guidance from health care professionals.

Dr. Califf’s extraordinary vision will help drive the development and delivery of innovative medical products and maintain the agency’s critical efforts to combat the significant public health threats posed by tobacco and unsafe food. 

In short, we could not be more pleased with the administration’s nomination of Dr. Califf. We look forward to working with an FDA led by him and we urge the Senate to confirm him as quickly as possible.”  


For media inquiries, please contact Retha Sherrod at or 202-785-7929